Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2020 11:19 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment

“Defensins are conceptually ideal for defense against different viral infections” WAKEFIELD, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a...
February 13, 2020 10:00 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin

Targeted colonic delivery shownDrug well-tolerated WAKEFIELD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical...
January 29, 2020 10:00 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate

WAKEFIELD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has further engaged Locust Walk, a...
January 24, 2020 11:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug

WAKEFIELD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company completed dosing in...
January 17, 2020 08:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Announces Dose Escalation

WAKEFIELD, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company has received...
January 16, 2020 12:00 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020

WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the...
December 26, 2019 08:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January

Patient screening positions Company for completion of a short clinical trialSignificant market demand for oral drugs in Inflammatory Bowel DiseaseBusiness development meetings scheduled during 2020...
December 13, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates

BEVERLY, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the United...
December 10, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

Targeting mid-year 2020 to commence clinical trials of Brilacidin for UP/UPS indicationRegulatory documents submitted to health authorities for planned Ulcerative Colitis study BEVERLY, Mass., Dec....
November 25, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals and FDA Agree to Waive Initial Pediatric Study Plan Requirement Regarding Brilacidin for the Prevention of Oral Mucositis

BEVERLY, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right